Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
what a bunch of garbage, time will tell.
so go ahead. lol.
At least once a week, another grey stock does a reverse split, such hogwash.
CANNOT ADD SHARES IS THE TERMINOLOGY> WOW HOW HARD IS IT>
NEVER MIND< I already know.
The lawyer is putting out info provided by the company. Not policing it. This company would be best suited to just be transparent about their endeavours. Why do they have an IR that does not respond or answer is scary. Why the company does not put the no mines argument to bed is even more scary.
Lets get one thing straight. The wording is cannot change share structure. Now it is, they cannot add shares. r/s does not change the share structure?
Thats about as absurd as non shorting and this company going nowhere. If this ticker goes back to pink, non of those arguments are going to matter and everyone knows it, yet there still is endless arguments about it. The only thing that tells me or anyone in the know, is, those are the ones that will soil themselves when it happens. That is the "FACT" here. Its awesome they cannot add shares. Just adds to the epic boom that will ensue. GLTA
Grey market stock troi* 1 for reverse split today. really
Agreement allows for RWB’s Illinois facility to provide thousands of pounds of premium and proprietary smokable hemp flower from 2020 harvests
TORONTO, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Red White & Bloom Brands Inc. (CSE: RWB) (OTC: RWBYF) (“RWB” or “Red White & Bloom”) is pleased to announce that they have entered into a Growing and Sales Agreement (the “Offtake”) with 39 Industries, LLC operating as Critical 39 (“Critical 39”), a Spokane, Washington based company focused on delivering premium products throughout the US.
Anne Hyde, President of Mid-American Growers, a wholly owned subsidiary of RWB, stated: "This Agreement with Critical 39 reflects our ability to attract partners that recognize our ability to provide indoor grown, ultra-premium products all year round. The combination of the robust genetics provided by Critical 39 and the skilled team at our Illinois facility will allow us to deliver finished goods that will command a premium price point and deliver on consumer demand for top shelf products.”
Under terms of the agreement, Critical 39 has already delivered 100,000 seeds to the 3.6 million square foot facility in Granville, Illinois where they are being cultivated in accordance with Good Agricultural Practices (“GAP”) and will be processed into finished whole hemp flower. The initial crop is expected to utilize a fraction of the facility’s capacity. The offtake has provisions for the parties to extend the relationship into the year 2022.
Lawrence Sowell, CEO of Critical 39, stated, “We are proud to partner with RWB to fulfill whole flower demand from our CPG distributors and end user consumers. This partnership allows us to further monetize on our premium genetics with a partner that has the greatest scale within the indoor premium hemp and CBD market. We anticipate this is just the first step of an expanding relationship.”
Generex Biotechnology Updates Agenda for Shareholder Conference Call on Wednesday August 26th, 2020 at 9:30 AM
Press Release | 08/19/2020
Letter of Intent (LOI) signed with potential partners in China to develop the Ii-Key-SARS-CoV-2 vaccine for China with a proposed $5 million upfront payment upon contract signing and minimum of $400 million if the vaccine is proven successful in clinical trials.
$20 Million Memorandum of Understanding completed with an investor for a strategic upmarket transaction, including a $10 Million financing proposal for the acquisition of infectious disease and cancer diagnostics company awaiting EUA approval from FDA for COVID-19 rapid diagnostic assay system
ALTuCELL acquisition update
NuGenHealth SaaS Remote Patient Monitoring and Chronic Care Management 50% Partnership
Completed a Memorandum of Understanding Regarding Development partnership for Ii-Key-SARS-CoV-2 in Malaysia worth up to $150 Million
MIRAMAR, Fla., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today updated the agenda for the shareholder conference call on Wednesday, August 26th at 9:30 am.
During the call, Generex President & CEO Joe Moscato will provide investors with an update on the significant corporate activities and goals that Generex has accomplished in the last several weeks. Highlights of the discussion include the overview of Generex’s signing of a Non-Binding Memorandum of Understanding concerning up-market financing for $20 million that will be used for Generex corporate initiatives and for the acquisition of a diagnostic company that has a platform for rapid, real-time results for infectious disease and cancer diagnoses. The platform is an integrated, automated system that utilizes real-time polymerase chain reaction technology (RT-PCR) to provide precise and accurate testing results that are available in 24 hours from sample collection. The diagnostic company has applied for emergency use authorization for its proprietary SARS-CoV-2 detection kit, which it plans to launch through a network of clinical laboratories, including a mobile testing lab that is fully equipped with the platform system. The financing is subject to several contingencies including satisfactory completion of legal and financial due diligence by the investor and Generex’s subsidiary NGIO being listed on Nasdaq.
In a new development, Generex has engaged with a potential partner in China and signed a LOI to develop the Ii-Key-SARS-CoV-2 vaccine for the Chinese market. The terms of the deal are currently being negotiated, however, when contracts are completed, and as outlined in the LOI, Generex will receive a $5 million upfront payment, and the Chinese partners will fund and conduct the clinical, manufacturing, laboratory, and regulatory work necessary to receive regulatory approval in China. Upon approval by the Chinese FDA, the LOI envisions manufacturing at least 200 million vaccine doses, with Generex receiving a minimum of $2 per dose of Ii-Key-SARS-CoV-2 vaccine.
The Generex team will provide an update on the ALTuCELL acquisition and progress being made with the ALTuCAP technology for cellular therapy.
Mr. Moscato will also discuss the company’s 50% partnership with a software as a Service (SaaS) company to provide chronic care management (CCM) and remote patient monitoring (RPM) that is scheduled to be deployed in collaboration with its partnered clinics in Arizona in the coming weeks.
Mr. Moscato will also provide details on the signing of a Non-binding Memorandum of Understanding with partners in Malaysia to develop and commercialize the Ii-Key-SARS-CoV-2 vaccine for the Malaysian population. The proposed deal includes full funding for the COVID-19 vaccine development, licensing fees, and sales of commercial vaccine product in Malaysia worth up to $150 million.
Mr. Moscato said, “We continue our efforts to realize the true value of our assets and intellectual properties for our dedicated shareholders, and we are optimistic that our discussions and negotiations regarding the development of our Ii-Key-SARS-CoV-2 vaccine will come to fruition shortly. I look forward to sharing details with shareholders on August 26th.
BennyMojo Member Level Thursday, 12/20/18 01:23:42 PM
Re: None 0
Post #
1882
of 15447
Spoke with Nick and says great new expected
buying all the cheapies I can
yes according to benny, its been coming tof 2 years now
Would be so nice to see they were on the list tomorrow.
Yeah, and I have seen the other side as well. They are an extremely competent, fair, non discriminating, best interest in mind etc, etc
group, right? lol.
meaningless was the post. Of course they will, but they are not going to damage their reputation by not fixing the very problems that instigated the situation in the first place. Gotta believe the situation for wrongdoing has been mitigated. Otherwise the companies efforts are fruitless and on that side of the fence, just ain't happenin. GLTU>
And do you think this is true with a very highly reputable sec attorney working on their behalf? Really? LMAO again.
We could only dream the ridiculousness would stop here.
SECURITIES AND EXCHANGE COMMISSION
Sunshine Act Meetings
TIME AND DATE: 2:00 p.m. on Wednesday, August 19, 2020.
PLACE: The meeting will be held via remote means and/or at the Commission's headquarters, 100 F Street, NE, Washington, DC 20549.
STATUS: This meeting will be closed to the public.
MATTERS TO BE CONSIDERED: Commissioners, Counsel to the Commissioners, the Secretary to the Commission, and recording secretaries will attend the closed meeting. Certain staff members who have an interest in the matters also may be present.
In the event that the time, date, or location of this meeting changes, an announcement of the change, along with the new time, date, and/or place of the meeting will be posted on the Commission's website at https://www.sec.gov.
The General Counsel of the Commission, or his designee, has certified that, in his opinion, one or more of the exemptions set forth in 5 U.S.C. 552b(c)(3), (5), (6), (7), (8), 9(B) and (10) and 17 CFR 200.402(a)(3), (a)(5), (a)(6), (a)(7), (a)(8), (a)(9)(ii) and (a)(10), permit consideration of the scheduled matters at the closed meeting.
The subject matter of the closed meeting will consist of the following topic:
Institution and settlement of injunctive actions;
Institution and settlement of administrative proceedings;
Resolution of litigation claims; and
Other matters relating to enforcement proceedings.
At times, changes in Commission priorities require alte
Rocket science would tell anyone the SEC has not done their job properly on a magnitude of levels. This a fact no one can deny. The travesty runs deep.
lmao.
If that is true, their loss. lol.
Exactly what its designed to do? They were designed to protect shareholders. Nothing they have done in the last year or more has been done to protect those same shareholders. They do not do their job, or they would not allow tickers currently 5 years without financials, WHICH IS TWICW AS LONG AS DBMM, STILL BE ON THE PINK MARKET. Their is no consistency in their actions, and a travesty to the shareholders of this stock. FACT.
? trips 6's were on level 2 yesterday.
Uh, there are 50 mil for the taking.
No apology necessary. I have serious bouts of the same illness, breaks up the monotony. GLTU>
uh, yes it did. lets hope there is a continuation.
WHERE ARE YOU SEEING THIS "P"?
Gee. people with covid experience chronic cough with covid. lol.
Yes, by all means, lets wait and see.
shoes on wrong foot. good luck.
Yes. And they have been getting away with it for 5 years. This is a good sign. Have those conversations amongst each other. lol.
Good observations. Now tell me the pps cannot go through the roof with even 1.5 billion outstanding. I do not even have to search. know one right now that is 2000% higher than where we are and know there are thousands. good luck with these analogies. crooked or not they go. lol.
Exactly, and that is why I need to have Eco reiterate the opportunities here moving forward. There really is not very much float needed to be locked up to send the pps to the astronomical levels we have thrown around here once the financials hit. This is just incredible with the structure.
for such an outlandish opportunity to make a boatload of cash with a very minimal lottery ticket, not many investors seem to agree. wonder why? They did not do well there last ticker? not too knowledgeable about what happened there.
Not sure, but saying 20 million shares were dumped is being just about as transparent.
A pill that may lessen COVID-related lung damage. Miami will be first in U.S. to test it
Caroline Ghisolfi
Miami HeraldAugust 7, 2020, 6:35 PM
A Miami hospital will be the first in the country to test a possible COVID-19 treatment on humans this August.
The research center at Westchester General Hospital in Coral Terrace is on its way to enroll patients to test Ifenprodil, a pill developed in the 1970s to treat blood circulation disorders that may alleviate some COVID-19 side-effects in the lungs.
The drug, which was tested on a coronavirus patient overseas for the first time Wednesday, may reduce the severity and duration of COVID-19 infections, according to Algernon Pharmaceuticals, a Canadian drug repurposing company that investigates pre-approved drugs for new disease applications and is now leading Ifenprodil’s COVID-19 testing.
“Just looking at the results of the research, it’s astonishing,” said Mark Williams, Algernon’s medical director. “Our drug might have a good chance at modulating the disease and hopefully reducing much of the damage that can occur in the lungs.”
Algernon will be testing the drug on 150 patients worldwide. Locations include Australia, Romania, the Philippines and the United States — with at least two locations in South Florida. Westchester General was the first site to be activated and will be investing $20,000 to $25,000 in the testing process, according to Williams.
Ifenprodil could treat a lung disease called Idiopathic Pulmonary Fibrosis, a “scarring or thickening of the lung tissue” that researchers fear is causing some COVID-19 deaths and could continue to threaten the lives of recovered patients after they leave the hospital, according to Algernon’s CEO, Christopher Moreau.
“It’s a very challenging condition to have because the average lifespan from the time of the diagnosis is about three years. And the tissue in the lungs starts to thicken and, as the disease progresses, there’s less and less oxygen in the blood,” Moreau explained.
There are two other drugs currently being considered to treat this specific coronavirus-induced disease: Pirfenidone, approved in the United States in 2014, and Nintedanib, approved in 2016. But Moreau and Williams believe that Ifenprodil could be a more effective treatment for COVID-19.
“Our drug works with a very different mechanism than [those of] other companies,” said Williams. “We’re helping boost and protect the patient instead of going after the disease.”
Ifenprodil’s breakthrough
Algernon announced on March 6 that it was going to look into the drug as a possible treatment for COVID-19 after discovering a promising independent research study conducted in China, Moreau said.
The study showed that the drug was able to reduce mortality by 40 percent in people affected by the world’s most lethal avian flu, the Asian Avian Influenza A — a rare disease that was first detected in humans in 1997 in Hong Kong and reemerged in Canada in 2014, according to the Centers for Disease Control and Prevention.
Seeing some promise in Ifenprodil, Algernon began conducting its own studies to see its effects on the lungs. And the results, Moreau said, were incredible.
“We did an animal study where we went up against the Merck drug Gefapixant — which is what’s mainly used now to treat chronic cough — and our drug outperformed Merck’s by 110 percent,” he said.
But the breakthrough came with a third study released on June 1 by the University of Texas at Dallas’ Center for Advanced Pain Studies, where researchers discovered that Ifenprodil is made up of a unique compound that could stop COVID-19 from killing lung cells.
Therapeutic treatment vs. vaccines
Moreau suggested that Ifenprofil could be safer than a rushed vaccine and may be released to the public sooner.
“We definitely need to be working on a vaccine, but there’s a great risk [in rushing] the development process because of what it could mean if it goes wrong,” he said.
Moreau compared the race to develop COVID-19 treatments to the one that started in the 1980s for HIV, for which a vaccine has still not been approved.
“They’ve been working on a vaccine for 25 years and haven’t found one yet, but they do have a number of therapeutic options, drug choices, that sort of form a cocktail,” he said. “So for COVID-19, we need to look at those options too. They may just be the global fix
Right on the ball, just rewrite your question as a statement and you will have the answer.
Who’s operating in the Guerrero Gold Belt?
Highlighting all the companies working in the Guerrero Gold Belt would be a gargantuan task Investing News Network
part of the region’s popularity stems from the financial advantages it holds. you really can’t get much cheaper than the oxide resources that are prevalent in the [Guerrero Gold Belt]. It gives us some of the cheapest gold production costs in the world.”
Guess peeps think it takes less than 24 hours to update documents with mitigating circumstances. Geez o wiz.
BennyMojo Member Level Tuesday, 02/05/19 11:08:15 PM
Re: None 0
Post #
3273
of 14641
Nick says BIG NEWS coming this week!!!
with new awareness campaign expect this stock to be at 25 cents
YOU GET THE PICTURE!!
BennyMojo Member Level Wednesday, 12/05/18 10:35:22 PM
Re: None 0
Post #
1795
of 14640
AABB short term $0.50 cents, long term $1.50.
BennyMojo Member Level Monday, 03/30/20 03:00:52 PM
Re: None 0
Post #
6948
of 14639
Kevin says GREAT NEWS coming!
BennyMojo Member Level Wednesday, 07/22/20 12:22:02 PM
Re: None 0
Post #
13662
of 14638
Super stoked about upcoming MEGA NEWS!!!
Here we go again. Tell him to give a shareholder update then. lol.